Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
HEART FAILURE / EXPERIMENTAL RESEARCH
Myrcene enhances the cardioprotective effect through matrix remodelling in an experimental model of heart failure
1
Department of Emergency, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China
2
Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China
Submission date: 2020-03-03
Final revision date: 2020-03-28
Acceptance date: 2020-04-01
Online publication date: 2020-06-15
Publication date: 2026-01-16
Corresponding author
Nan Lin
Department of Emergency The Affiliated Hospital of Qingdao University 16 Jiangsu Road Shinan District Qingdao 266000 Shandong Province China Phone/fax: +86 532 8291 1283
Department of Emergency The Affiliated Hospital of Qingdao University 16 Jiangsu Road Shinan District Qingdao 266000 Shandong Province China Phone/fax: +86 532 8291 1283
Arch Med Sci 2025;21(6):2814-2825
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Myrcene, a terpene found in essential oils sourced from plants, is known to elicit various biological effects such as antioxidant, anti-inflammatory, hypoglycaemic, and hepatoprotective activities. However, reports on the protective effect of myrcene against heart failure are still not clear. Hence, in the present study, the experimental model of heart failure was induced using isoproterenol in rats.
Material and methods:
Wistar male rats were divided into four groups: group I – Control; group II – ISO-induced heart failure; group III – Myrcene pre-treated (1.0 mg/kg/day and ISO); and group IV – Myrcene drug control for the experimental period of 4 weeks. At the end of the treatment, infarct size, cardiac markers, cell stress enzymes such as creatinine kinase, lactate dehydrogenase, inflammatory markers, matrix proteins, and microRNA signatures were elucidated using RT-PCR, ELISA, and immunohistochemistry analysis.
Results:
Rats with induced heart failure demonstrated abnormality in cardiac functions and marker gene expressions, while myrcene pre-treated rats prevented cardiac failure significantly (p < 0.001) with restoration of cellular functions. Also, myrcene pre-treatment abrogated the inflammatory signals with restored matrix proteins. Furthermore, the microRNA of matrix signalling pathways were also found to be prominently reduced compared to heart failure rats.
Conclusions:
Myrcene protected hearts from ISO-induced failure in rats and provided a cardioprotective effect via restoring the matrix signalling, anti-inflammatory, and antioxidant effect, which suggests a possible drug candidature for the treatment of cardiac failure.
Myrcene, a terpene found in essential oils sourced from plants, is known to elicit various biological effects such as antioxidant, anti-inflammatory, hypoglycaemic, and hepatoprotective activities. However, reports on the protective effect of myrcene against heart failure are still not clear. Hence, in the present study, the experimental model of heart failure was induced using isoproterenol in rats.
Material and methods:
Wistar male rats were divided into four groups: group I – Control; group II – ISO-induced heart failure; group III – Myrcene pre-treated (1.0 mg/kg/day and ISO); and group IV – Myrcene drug control for the experimental period of 4 weeks. At the end of the treatment, infarct size, cardiac markers, cell stress enzymes such as creatinine kinase, lactate dehydrogenase, inflammatory markers, matrix proteins, and microRNA signatures were elucidated using RT-PCR, ELISA, and immunohistochemistry analysis.
Results:
Rats with induced heart failure demonstrated abnormality in cardiac functions and marker gene expressions, while myrcene pre-treated rats prevented cardiac failure significantly (p < 0.001) with restoration of cellular functions. Also, myrcene pre-treatment abrogated the inflammatory signals with restored matrix proteins. Furthermore, the microRNA of matrix signalling pathways were also found to be prominently reduced compared to heart failure rats.
Conclusions:
Myrcene protected hearts from ISO-induced failure in rats and provided a cardioprotective effect via restoring the matrix signalling, anti-inflammatory, and antioxidant effect, which suggests a possible drug candidature for the treatment of cardiac failure.
REFERENCES (46)
1.
Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G. Guideline ESCCFP Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384-416.
2.
Zhang Z, Wang B, Fei A. BDNF contributes to the skeletal muscle anti-atrophic effect of exercise training through AMPK-PGC1alpha signaling in heart failure mice. Arch Med Sci 2019; 15: 214-22.
3.
Omland T. Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure. Crit Care Med 2008; 36 (1 Suppl): S17-27.
4.
Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res 2016; 365: 563-81.
5.
Michalska-Kasiczak M, Bielecka-Dabrowa A, von Haehling S, Anker S, Rysz J, Banach M. Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview. Arch Med Sci 2018; 14: 890-909.
6.
Lin YH, Lin LY, Wu YW, et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009; 409: 96-9.
7.
Lombardi R, Betocchi S, Losi MA, et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation 2003; 108: 1455-60.
8.
Ma Y, de Castro Bras LE, Toba H, et al. Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling. Pflugers Arch 2014; 466: 1113-27.
9.
Katz AM, Zile MR. New molecular mechanism in diastolic heart failure. Circulation 2006; 113: 1922-5.
10.
Mocan M, Mocan Hognogi LD, Anton FP, et al. Biomarkers of inflammation in left ventricular diastolic dysfunction. Dis Markers 2019; 2019: 7583690.
11.
de Cassia da Silveira e Sa R, Andrade LN, de Sousa DP. A review on anti-inflammatory activity of monoterpenes. Molecules 2013; 18: 1227-54.
12.
Rufino AT, Ribeiro M, Sousa C, et al. Evaluation of the anti-inflammatory, anti-catabolic and pro-anabolic effects of E-caryophyllene, myrcene and limonene in a cell model of osteoarthritis. Eur J Pharmacol 2015; 750: 141-50.
13.
Hwang E, Ngo HTT, Park B, Seo SA, Yang JE, Yi TH. Myrcene, an aromatic volatile compound, ameliorates human skin extrinsic aging via regulation of MMPs production. Am J Chin Med 2017; 45: 1113-24.
14.
Subramanian U, Kumar P, Mani I, et al. Retinoic acid and sodium butyrate suppress the cardiac expression of hypertrophic markers and proinflammatory mediators in Npr1 gene-disrupted haplotype mice. Physiol Genomics 2016; 48: 477-90.
15.
Umadevi S, Gopi V, Elangovan V. Regulatory mechanism of gallic acid against advanced glycation end products induced cardiac remodeling in experimental rats. Chem Biol Interact 2014; 208: 28-36.
16.
Molojavyi A, Lindecke A, Raupach A, Moellendorf S, Kohrer K, Godecke A. Myoglobin-deficient mice activate a distinct cardiac gene expression program in response to isoproterenol-induced hypertrophy. Physiol Genomics 2010; 41: 137-45.
17.
Li L, Zhao Q, Kong W. Extracellular matrix remodeling and cardiac fibrosis. Matrix Biol 2018; 68-69: 490-506.
18.
Zhou R, Xu Q, Zheng P, Yan L, Zheng J, Dai G. Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat. Eur J Pharmacol 2008; 586: 244-50.
19.
Sun JM, Wang CM, Guo Z, et al. Reduction of isoproterenol-induced cardiac hypertrophy and modulation of myocardial connexin43 by a KATP channel agonist. Mol Med Rep 2015; 11: 1845-50.
20.
Zahabi A, Picard S, Fortin N, Reudelhuber TL, Deschepper CF. Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts. J Biol Chem 2003; 278: 47694-9.
21.
Patel V, Upaganlawar A, Zalawadia R, Balaraman R. Cardioprotective effect of melatonin against isoproterenol induced myocardial infarction in rats: a biochemical, electrocardiographic and histoarchitectural evaluation. Eur J Pharmacol 2010; 644: 160-8.
22.
Cihak R, Kolar F, Pelouch V, Prochazka J, Ostadal B, Widimsky J. Functional changes in the right and left ventricle during development of cardiac hypertrophy and after its regression. Cardiovasc Res 1992; 26: 845-50.
23.
Tang L, Taylor PB. Altered contractile function in isoproterenol-induced hypertrophied rat heart. J Hypertens 1996; 14: 751-7.
24.
Rao VS, Menezes AM, Viana GS. Effect of myrcene on nociception in mice. J Pharm Pharmacol 1990; 42: 877-8.
25.
Lee H, Woo M, Kim M, Noh JS, Song, YO. Antioxidative and cholesterol-lowering effects of lemon essential oil in hypercholesterolemia-induced rabbits. Prev Nutr Food Sci 2018; 23: 8-14.
26.
Gavras I, Manolis AJ, Gavras H. The alpha2-adrenergic receptors in hypertension and heart failure: experimental and clinical studies. J Hypertens 2001; 19: 2115-24.
27.
Sax H, Contesse J, Dubach P, Reinhart WH. Creatine kinase MB during myocardial infarction: relationship to preexisting coronary heart disease and medication. Acta Cardiol 1997; 52: 423-30.
28.
Adams JE 3rd, Bodor GS, Dávila-Román VG, et al. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation 1993; 88: 101-6.
29.
Apple FS. Tissue specificity of cardiac troponin I, cardiac troponin T and creatine kinase-MB. Clin Chim Acta 1999; 284: 151-9.
30.
Preus M, Bhargava AS, Khater AE, Gunzel P. Diagnostic value of serum creatine kinase and lactate dehydrogenase isoenzyme determinations for monitoring early cardiac damage in rats. Toxicol Lett 1988; 42: 225-33.
31.
Jingu Y, Aoki Y, Itoh H, Saruta T. Serum creatine kinase release and alpha- and beta-adrenergic receptors. Arch Int Pharmacodyn Ther 1986; 282: 262-75.
32.
Rajadurai M, Prince PS. Preventive effect of naringin on isoproterenol-induced cardiotoxicity in Wistar rats: an in vivo and in vitro study. Toxicology 2007; 232: 216-25.
33.
Holland RP, Brooks H. TQ-ST segment mapping: critical review and analysis of current concepts. Am J Cardiol 1977; 40: 110-29.
34.
Al-Rasheed NM, Al-Oteibi MM, Al-Manee RZ, et al. Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway. Drug Des Devel Ther 2015; 9: 3217-29.
35.
Ramani R, Mathier M, Wang P, et al. Inhibition of tumor necrosis factor receptor-1-mediated pathways has beneficial effects in a murine model of postischemic remodeling. Am J Physiol Heart Circ Physiol 2004; 287: H1369-77.
36.
Burton OT, Darling AR, Zhou JS, et al. Direct effects of IL-4 on mast cells drive their intestinal expansion and increase susceptibility to anaphylaxis in a murine model of food allergy. Mucosal Immunol 2013; 6: 740-50.
37.
Peng H, Sarwar Z, Yang XP, et al. Profibrotic role for interleukin-4 in cardiac remodeling and dysfunction. Hypertension 2015; 66: 582-9.
38.
Brower GL, Gardner JD, Forman MF, et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 2006; 30: 604-10.
39.
Souza MC, Siani AC, Ramos MF, Menezes-de-Lima OJ, Henriques MG. Evaluation of anti-inflammatory activity of essential oils from two Asteraceae species. Pharmazie 2003; 58: 582-6.
40.
Westermann D, Lindner D, Kasner M, et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 2011; 4: 44-52.
41.
Kato TS, Chokshi A, Singh P, et al. Markers of extracellular matrix turnover and the development of right ventricular failure after ventricular assist device implantation in patients with advanced heart failure. J Heart Lung Transplant 2012; 31: 37-45.
42.
Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007; 87: 1285-42.
43.
Yang YJ, Zhang X, Zhu WL, Huang Y. Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure. Zhonghua Yi Xue Za Zhi 2006; 86: 1693-6.
44.
Montgomery RL, Hullinger TG, Semus HM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011; 124: 1537-47.
45.
Lew WY, Bayna E, Dalle Molle E, Contu R, Condorelli G, Tang T. Myocardial fibrosis induced by exposure to subclinical lipopolysaccharide is associated with decreased miR-29c and enhanced NOX2 expression in mice. PLoS One 2014; 9: e107556.
46.
Sucharov C, Bristow MR, Port JD. miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol 2008; 45: 185-92.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
